334 related articles for article (PubMed ID: 36087505)
21. Phenotype and biochemical heterogeneity in late onset Fabry disease defined by N215S mutation.
Lavalle L; Thomas AS; Beaton B; Ebrahim H; Reed M; Ramaswami U; Elliott P; Mehta AB; Hughes DA
PLoS One; 2018; 13(4):e0193550. PubMed ID: 29621274
[TBL] [Abstract][Full Text] [Related]
22. Variations in the GLA gene correlate with globotriaosylceramide and globotriaosylsphingosine analog levels in urine and plasma.
Ferreira S; Auray-Blais C; Boutin M; Lavoie P; Nunes JP; Martins E; Garman S; Oliveira JP
Clin Chim Acta; 2015 Jul; 447():96-104. PubMed ID: 26070511
[TBL] [Abstract][Full Text] [Related]
23. Lyso-Gb3 associates with adverse long-term outcome in patients with Fabry disease.
Nowak A; Beuschlein F; Sivasubramaniam V; Kasper D; Warnock DG
J Med Genet; 2022 Mar; 59(3):287-293. PubMed ID: 33495303
[TBL] [Abstract][Full Text] [Related]
24. Globotriaosylsphingosine (Lyso-Gb
Alharbi FJ; Baig S; Auray-Blais C; Boutin M; Ward DG; Wheeldon N; Steed R; Dawson C; Hughes D; Geberhiwot T
J Inherit Metab Dis; 2018 Mar; 41(2):239-247. PubMed ID: 29294190
[TBL] [Abstract][Full Text] [Related]
25. Reduced glucosylceramide in the mouse model of Fabry disease: correction by successful enzyme replacement therapy.
Quinta R; Rodrigues D; Assunção M; Macedo MF; Azevedo O; Cunha D; Oliveira P; Sá Miranda MC
Gene; 2014 Feb; 536(1):97-104. PubMed ID: 24334116
[TBL] [Abstract][Full Text] [Related]
26. Nano-LC-MS/MS for Quantification of Lyso-Gb3 and Its Analogues Reveals a Useful Biomarker for Fabry Disease.
Sueoka H; Ichihara J; Tsukimura T; Togawa T; Sakuraba H
PLoS One; 2015; 10(5):e0127048. PubMed ID: 25965380
[TBL] [Abstract][Full Text] [Related]
27. Anti-drug antibody formation in Japanese Fabry patients following enzyme replacement therapy.
Tsukimura T; Tayama Y; Shiga T; Hirai K; Togawa T; Sakuraba H
Mol Genet Metab Rep; 2020 Dec; 25():100650. PubMed ID: 33072516
[TBL] [Abstract][Full Text] [Related]
28. Systematic gene therapy derived from an investigative study of AAV2/8 vector gene therapy for Fabry disease.
Deng M; Zhou H; He S; Qiu H; Wang Y; Zhao AY; Mu Y; Li F; Zhao AZ
Orphanet J Rare Dis; 2023 Sep; 18(1):275. PubMed ID: 37670350
[TBL] [Abstract][Full Text] [Related]
29. Assessment and impact of dose escalation on anti-drug antibodies in Fabry disease.
Lenders M; Brand E
Front Immunol; 2022; 13():1024963. PubMed ID: 36569886
[TBL] [Abstract][Full Text] [Related]
30. Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy.
van Breemen MJ; Rombach SM; Dekker N; Poorthuis BJ; Linthorst GE; Zwinderman AH; Breunig F; Wanner C; Aerts JM; Hollak CE
Biochim Biophys Acta; 2011 Jan; 1812(1):70-6. PubMed ID: 20851180
[TBL] [Abstract][Full Text] [Related]
31. Multiplex tandem mass spectrometry analysis of novel plasma lyso-Gb₃-related analogues in Fabry disease.
Boutin M; Auray-Blais C
Anal Chem; 2014 Apr; 86(7):3476-83. PubMed ID: 24634980
[TBL] [Abstract][Full Text] [Related]
32. Late-onset and classic phenotypes of Fabry disease in males with the
Valtola K; Hedman M; Kantola I; Walls S; Helisalmi S; Maria M; Raivo J; Auray-Blais C; Kuusisto J
Open Heart; 2023 Mar; 10(1):. PubMed ID: 36927868
[TBL] [Abstract][Full Text] [Related]
33. Glucosylceramide synthase inhibition with lucerastat lowers globotriaosylceramide and lysosome staining in cultured fibroblasts from Fabry patients with different mutation types.
Welford RWD; Mühlemann A; Garzotti M; Rickert V; Groenen PMA; Morand O; Üçeyler N; Probst MR
Hum Mol Genet; 2018 Oct; 27(19):3392-3403. PubMed ID: 29982630
[TBL] [Abstract][Full Text] [Related]
34. Cardiac manifestations of Fabry disease in G3Stg/GlaKO and GlaKO mouse models-Translation to Fabry disease patients.
Kugadas A; Artoni P; Ruangsiriluk W; Zhao M; Boukharov N; Islam R; Volfson D; Derakhchan K
PLoS One; 2024; 19(5):e0304415. PubMed ID: 38820517
[TBL] [Abstract][Full Text] [Related]
35. The prevalence of Fabry disease among 1009 unrelated patients with hypertrophic cardiomyopathy: a Russian nationwide screening program using NGS technology.
Savostyanov K; Pushkov A; Zhanin I; Mazanova N; Trufanov S; Pakhomov A; Alexeeva A; Sladkov D; Asanov A; Fisenko A
Orphanet J Rare Dis; 2022 May; 17(1):199. PubMed ID: 35578305
[TBL] [Abstract][Full Text] [Related]
36. A phase II, multicenter, open-label trial to evaluate the safety and efficacy of ISU303 (Agalsidase beta) in patients with Fabry disease.
Hwang S; Lee BH; Kim WS; Kim DS; Cheon CK; Lee CH; Choi Y; Choi JH; Kim JH; Yoo HW
Medicine (Baltimore); 2022 Sep; 101(37):e30345. PubMed ID: 36123934
[TBL] [Abstract][Full Text] [Related]
37. A Rapid and Simple UHPLC-MS/MS Method for Quantification of Plasma Globotriaosylsphingosine (lyso-Gb3).
Perrone A; Mohamed S; Donadio V; Liguori R; Contin M
Molecules; 2021 Dec; 26(23):. PubMed ID: 34885938
[TBL] [Abstract][Full Text] [Related]
38. Safety and effectiveness of enzyme replacement therapy with agalsidase alfa in patients with Fabry disease: Post-marketing surveillance in Japan.
Sasa H; Nagao M; Kino K
Mol Genet Metab; 2019 Apr; 126(4):448-459. PubMed ID: 30803893
[TBL] [Abstract][Full Text] [Related]
39. Mechanisms of Neutralizing Anti-drug Antibody Formation and Clinical Relevance on Therapeutic Efficacy of Enzyme Replacement Therapies in Fabry Disease.
Lenders M; Brand E
Drugs; 2021 Nov; 81(17):1969-1981. PubMed ID: 34748189
[TBL] [Abstract][Full Text] [Related]
40. A Fabry Disease Patient Who Developed Hypersensitivity Reaction against Agalsidase Beta following COVID-19 Infection.
Sonmez O; Ozcan SG; Trabulus S; Seyahi N
Nephron; 2023; 147(3-4):199-202. PubMed ID: 36174537
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]